Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs AR-targeted agent in mCRPC (CARD)
NCT02485691Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2015
- Primary completion
- Mar 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 13
01
Overview
A Phase 4 trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Nov 2015; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02485691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485691.